Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Identification of novel HNF1B mRNA splicing variants and their qualitative and semi-quantitative profile in selected healthy and tumour tissues

J. Hojny, M. Bartu, E. Krkavcova, K. Nemejcova, J. Sevcik, D. Cibula, V. Fryba, L. Plincelnerova, P. Dundr, I. Struzinska,

. 2020 ; 10 (1) : 6958. [pub] 20200424

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20028242

Grant support
NV17-28404A MZ0 CEP Register

Hepatocyte nuclear factor-1-beta (HNF1B) is a transcription factor crucial for the development of several tissues, and a promising biomarker of certain solid tumours. Thus far, two HNF1B alternative splicing variants (ASVs) have been described, however, the complete spectrum, prevalence and role of HNF1B ASVs in tumorigenesis are unclear. Considering the equivocal data about HNF1B ASVs and expression presented in literature, our aim was to characterize the spectrum of HNF1B mRNA splicing variants across different tissues. Here, we characterize HNF1B ASVs with high sensitivity in carcinomas of the uterine corpus, large intestine, kidney, pancreas, and prostate, with selected paired healthy tissues, using the previously described multiplex PCR and NGS approach. We identified 45 ASVs, of which 43 were novel. The spectrum and relative quantity of expressed ASVs mRNA differed among the analysed tissue types. Two known (3p, Δ7_8) and two novel (Δ7, Δ8) ASVs with unknown biological functions were detected in all the analysed tissues in a higher proportion. Our study reveals the wide spectrum of HNF1B ASVs in selected tissues. Characterization of the HNF1B ASVs is an important prerequisite for further expression studies to delineate the HNF1B splicing pattern, potential ASVs functional impact, and eventual refinement of HNF1B's biomarker role.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028242
003      
CZ-PrNML
005      
20210114153316.0
007      
ta
008      
210105s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-020-63733-x $2 doi
035    __
$a (PubMed)32332782
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Hojny, Jan $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, 12808, Czech Republic.
245    10
$a Identification of novel HNF1B mRNA splicing variants and their qualitative and semi-quantitative profile in selected healthy and tumour tissues / $c J. Hojny, M. Bartu, E. Krkavcova, K. Nemejcova, J. Sevcik, D. Cibula, V. Fryba, L. Plincelnerova, P. Dundr, I. Struzinska,
520    9_
$a Hepatocyte nuclear factor-1-beta (HNF1B) is a transcription factor crucial for the development of several tissues, and a promising biomarker of certain solid tumours. Thus far, two HNF1B alternative splicing variants (ASVs) have been described, however, the complete spectrum, prevalence and role of HNF1B ASVs in tumorigenesis are unclear. Considering the equivocal data about HNF1B ASVs and expression presented in literature, our aim was to characterize the spectrum of HNF1B mRNA splicing variants across different tissues. Here, we characterize HNF1B ASVs with high sensitivity in carcinomas of the uterine corpus, large intestine, kidney, pancreas, and prostate, with selected paired healthy tissues, using the previously described multiplex PCR and NGS approach. We identified 45 ASVs, of which 43 were novel. The spectrum and relative quantity of expressed ASVs mRNA differed among the analysed tissue types. Two known (3p, Δ7_8) and two novel (Δ7, Δ8) ASVs with unknown biological functions were detected in all the analysed tissues in a higher proportion. Our study reveals the wide spectrum of HNF1B ASVs in selected tissues. Characterization of the HNF1B ASVs is an important prerequisite for further expression studies to delineate the HNF1B splicing pattern, potential ASVs functional impact, and eventual refinement of HNF1B's biomarker role.
650    _2
$a alternativní sestřih $x genetika $7 D017398
650    _2
$a biologické markery $x metabolismus $7 D015415
650    _2
$a hepatocytární jaderný faktor 1-beta $x genetika $x metabolismus $7 D051539
650    _2
$a lidé $7 D006801
650    _2
$a ledviny $x metabolismus $x patologie $7 D007668
650    _2
$a multiplexová polymerázová řetězová reakce $7 D060885
650    _2
$a pankreas $x metabolismus $x patologie $7 D010179
650    _2
$a sestřih RNA $x genetika $7 D012326
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bartu, Michaela $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, 12808, Czech Republic.
700    1_
$a Krkavcova, Eva $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, 12808, Czech Republic.
700    1_
$a Nemejcova, Kristyna $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, 12808, Czech Republic.
700    1_
$a Sevcik, Jan $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, 12853, Czech Republic.
700    1_
$a Cibula, David $u Gynecological Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, 12851, Czech Republic.
700    1_
$a Fryba, Vladimir $u 1st Department of Surgery - Department of Abdominal, Thoracic Surgery and Traumatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, 12808, Czech Republic.
700    1_
$a Plincelnerova, Lenka $u Department of Urology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, 12808, Czech Republic.
700    1_
$a Dundr, Pavel $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, 12808, Czech Republic.
700    1_
$a Struzinska, Ivana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, 12808, Czech Republic. ivana.struzinska@vfn.cz.
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 10, č. 1 (2020), s. 6958
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32332782 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114153313 $b ABA008
999    __
$a ok $b bmc $g 1608577 $s 1119422
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 10 $c 1 $d 6958 $e 20200424 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
GRA    __
$a NV17-28404A $p MZ0
LZP    __
$a Pubmed-20210105

Find record

Citation metrics

Archiving options